Please login to the form below

Not currently logged in

Dr Simon Chandler joins Ora as a senior director

He brings 15 years of ophthalmic industry experience 

Ora Simon ChandlerUS-based Ora, inc. has appointed Dr Simon Chandler as senior director, clinical research and regulatory operations.

Dr Chandler will be based at the pharmaceutical company's UK office and takes on responsibility for driving its European regulatory and clinical business.

He said: “I have personally experienced the quality, timely execution and strategic planning Ora delivers to ensure successful programs for their industry partners.

“I am proud to be joining a company with proven expertise in ophthalmology and a deep commitment to scientific rigor and innovation.”

He brings over 15 years of ophthalmic industry experience to the role, specialising in retina and anterior segment indications.

Prior to joining Ora, Dr Chandler served as principal of Sci-pHecta Consulting from 2013 and has also held leadership roles at Bausch + Lamb, Ista Pharmaceuticals, NightStaRx BioPharmaceuticals and Oxford BioMedica among others.

Ora's president and chief executive officer Stuart Abelson said: “Dr Chandler is a key addition to Ora's team and brings extensive experience in global clinical and regulatory operations, including overseeing approvals by the FDA, EMA and PMDA.

“His current experience in gene therapy is highly relevant given the potential of this new therapeutic modality to address unmet patient needs.”

5th April 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...